Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
- 17 July 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 30 (6) , 755-765
Abstract
The partial correction of anemia and the normalization of phosphate and blood pressure are the mainstay of treatment of patients with chronic kidney disease (CKD). Available anti-hypertensive drugs, erythropoiesis stimulating agents (ESAs) and iron supplements have resolved quite satisfactorily the goal of controlling hypertension and partially correcting anemia. Unfortunately, the treatment of hyperphosphatemia is still far from resolved. Phosphate binders have poor tolerability and/or limited efficacy, leading to the prescription of many tablets that achieve only a mild-to-moderate effect. Moreover, increased consumption of tablets is associated with increased low tolerability, thus jeopardizing patient compliance and, in turn, the efficacy of phosphate binding. Compared to calcium-free binders, the cheaper calcium salts increase the risk of hypercalcemia, calciphylaxis and vascular calcification and possibly all-cause mortality. Calcium-free phosphate binders decrease serum phosphate levels without increasing the serum calcium concentration. The higher phosphate-binding efficacy of lanthanum carbonate compared to sevelamer should be balanced against its lack of pleiotropic effects on lipid metabolism and inflammation and the accumulation in bones. New iron-based phosphate binders are available. In addition to their phosphate binding capacity, they could also be useful to treat anemia. Iron citrate is seeking for such an indication because its iron absorption is significant. This could be of clinical importance, particularly in CKD patients not on dialysis, obviating the need for extra oral iron administration and possibly favoring compliance. In conclusion, the use of iron-based phosphate binders with significant iron absorption properties could represent a novel paradigm for correcting anemia and hyperphosphatemia in CKD patients.Keywords
This publication has 88 references indexed in Scilit:
- Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort StudyPLOS ONE, 2013
- Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset modelInternational Journal of Nephrology and Renovascular Disease, 2013
- Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cellsNephrology Dialysis Transplantation, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney DiseaseCirculation, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Hyperphosphatemia of chronic kidney diseaseKidney International, 2008
- Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendationsOsteopathic Medicine and Primary Care, 2007